← Leaderboards
Anthony Sung
Duke University
$6,109,667
Attributed
$7,110,073
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,110,073 · 5
By mechanism
R01$6,345,323 · 3
R21$442,750 · 1
R03$322,000 · 1
Top collaborators
- Anna E Arthur2 shared
- Nelson J. Chao2 shared
Most similar at Duke University
Same institution · by research overlap
- Zeljko Vujaskovic$8,973,407
- David R Mc Clay$17,525,339
- David Reardon$8,732,934
- Kensaku Kawamoto$10,439,320
- Amy M Pastva$3,249,097
Others in their field
Other Emerging Leaders on “Primary Endpoint”
- Beth Baseler · Leidos Biomedical Research, Inc.$105,136,677
- Greg Yothers · University Of Chicago$25,122,895
- Abraham Aizer Brody · New York University School Of Medicine$15,928,507
- Wendy Bergantz · University Of Chicago$13,233,874
- Yunda Huang · Fred Hutchinson Cancer Center$12,614,030
- Andrew S Huhn · Johns Hopkins University$12,205,195
Research focus
Primary EndpointTransplant RecipientsHematopoietic Stem Cell TransplantationReportingRandomizedImproved OutcomeAntibioticsAffectSuccessMortalityPhase Iii TrialPhase Ii TrialMediatingFutureSymptomsGraft Vs Host DiseaseNovel StrategiesAllogenicNutritionMalignant NeoplasmsMalignant - DescriptorInfectionHospitalizationCaring
Grant awards (16)
Addressing Malnutrition in Transplant and Cellular Therapy Patients with Healthcare-Food Bank Partnerships$749,218
R01 · FY2025 · NR · contact PI
Home-based Autologous Hematopoietic Stem Cell Transplantation to ImproveOutcomes and Decrease Costs$439,660
R01 · FY2025 · AG · contact PI
Addressing Food Insecurity in Transplant and Cellular Therapy Patients with Healthcare-Community Partnerships$808,845
R01 · FY2024 · NR · contact PI
Home-based Autologous Hematopoietic Stem Cell Transplantation to Improve Outcomes and Decrease Costs$615,276
R01 · FY2024 · AG · contact PI
Prebiotics to Optimize the Microbiota and Improve Outcomes of AllogeneicHematopoietic Stem Cell Transplantation$348,750
R01 · FY2024 · HL · contact PI
Prebiotics to Optimize the Microbiota and Improve Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation$362,250
R01 · FY2023 · HL · contact PI
Home-based Autologous Hematopoietic Stem Cell Transplantation to Improve Outcomes and Decrease Costs$629,927
R01 · FY2022 · AG · contact PI
Prebiotics to Optimize the Microbiota and Improve Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation$362,250
R01 · FY2022 · HL · contact PI
Hematopoietic Stem Cell Transplantation Combined with CSF1 Inhibition to Attenuate the Pathogenesis of Alzheimer's Disease$161,000
R03 · FY2022 · AG · contact PI
Home-based Autologous Hematopoietic Stem Cell Transplantation to Improve Outcomes and Decrease Costs$644,547
R01 · FY2021 · AG · contact PI
Prebiotics to Optimize the Microbiota and Improve Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation$362,250
R01 · FY2021 · HL · contact PI
Hematopoietic Stem Cell Transplantation Combined with CSF1 Inhibition to Attenuate the Pathogenesis of Alzheimer's Disease$161,000
R03 · FY2021 · AG · contact PI
Home-based Autologous Hematopoietic Stem Cell Transplantation to Improve Outcomes and Decrease Costs$660,100
R01 · FY2020 · AG · contact PI
Prebiotics to Optimize the Microbiota and Improve Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation$362,250
R01 · FY2020 · HL · contact PI
Evaluating Effects of Age-related Microbiota Modulations in Hematopoietic Stem Cell Transplant Patients$201,250
R21 · FY2020 · AG · contact PI
Evaluating Effects of Age-related Microbiota Modulations in Hematopoietic Stem Cell Transplant Patients$241,500
R21 · FY2019 · AG · contact PI